Image Credit: Adobe Stock Images/VILevi.com The purpose of Medicaid’s 340B Drug Pricing Program is to grant the participating safety-net hospitals and clinics with incentives—in the form of discounts—from pharma companies on certain outpatient drugs, while billing insurers general reimbursement rates. In other words, says the Health Resources & Services Administration,…
-
-
Adobe Stock Images/Preyanuch.com Independent Pharmacy Cooperative (IPC), a group purchasing organization consisting of community pharmacies, has reached a new supply agreement1 with McKesson, a drug wholesaler that’s considered a part of the industry’s “Big Three.” The deal had been about a year in the making, and IPC noted that it…
-
Image Credit: Adobe Stock Images/Grinny.com Hypertension—also known as high blood pressure—is a health issue that impacts close to half of the population in the United States. Given its magnitude, many patients are aware of the daily follow-up appointments with the clinical care team that are needed in order to not…
-
Image Credit: Adobe Stock Images/Ayesha.com Charles River Laboratories International, Inc., a contract development and manufacturing organization (CDMO), and the Gates Institute at the University of Colorado Anschutz Medical Campus have reached a lentiviral vector manufacturing agreement.1 Per the deal, Gates Institute will utilize Charles River’s cell and gene therapy (CGT) expertise—especially in the manufacturing space—to develop…
-
Image Credit: Adobe Stock Images/RyanKing999.com ANI Pharmaceuticals, Inc., a biopharma company in the branded and generic prescription sector, and Alimera Sciences, Inc., who operates in the retinal health space, has purchased Alimera for approximately $381 million.1 Per the deal, this equates to $5.50 per share in cash at closing, while…
-
Image Credit: ProBio Inc. ProBio Inc, a contract development and manufacturing organization (CDMO) that is also known as GenScript ProBio, will be growing its plasmid DNA (pDNA) and viral vector manufacturing services by opening a new 128,000 square-foot plant in Hopewell, NJ.1 This new facility will operate as the hub for…
-
PC: How are changing reimbursement models impacting patient access to therapies in the space? As you know, even if a drug were to make it to market, questions remain as to whether it will be covered by insurance or even added to a national preferred formulary, making it difficult for…
-
Image Credit: Adobe Stock Images/iDoPixBox.com When it comes to the treatment of unresectable locally advanced stage III non–small cell lung cancer (NSCLC), the standard of care process features definitive chemoradiotherapy, followed by maintenance immunotherapy with durvalumab. In these instances, the obstacle is durvalumab’s cost of use in health systems, along…
-
DIA 2024: Gareth Dabbs of IQVIA Discusses Challenges With Clinical Technology In an interview with editor Andy Studna at DIA 2024, Dabbs, vice president, global product strategy, IQVIA highlights challenges with tech overload and how stakeholders can choose which solution(s) are best for their studies. Exploring the Connection Between Orange…
-
Image Credit: Adobe Stock Images/Nina.com Ascidian Therapeutics, a biotech company, has entered a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon-editing therapeutics that target neurological diseases.1 Ascidian—whose efforts revolve around rewriting RNA—has an RNA exon editing platform that is intended to further the…